Amylin, a peptide copackaged with insulin in j-cell granules, was measured in the effluent of the perfused rat pancreas by means of a newly developed specific radioimmunoassay. Its secretion parallels that of insulin in response to 20 mM glucose, 10 mM arginine, or the combination thereof. 
Introduction
Amylin (or islet amyloid polypeptide) is a 37-amino acid peptide that was initially identified as the main constituent of islet amyloid in subjects with noninsulin-dependent diabetes mellitus (1) (2) (3) (4) and has been shown to modify insulin's effects in skeletal muscle (5) (6) (7) . It is derived from a 93-amino acid precursor molecule in rat (8) or an 89-amino acid precursor in man (9, 10) . Amylin mRNA is found in rat pancreatic islets and is not present in other tissues (8) (14) .
Secretionfrom perfused rat pancreas. Pancreata of Wistar rats were isolated and perfused by the method of Grodsky and Fanska (16), as modified by Hisatomi et al. (17) . The perfusate was KRB buffer containing 4.5% Dextran T70, 5.6 mM glucose, 1% bovine serum albumin, and 5 mM each of sodium pyruvate, sodium glutamate, and sodium fumarate. The flow rate was 2.7 ml/min. After a 10-15-min equilibration period, the pancreas was perfused for 10 min with 5.6 mM glucose. 10-min stimulatory periods with 20 mM glucose, 10 mM arginine, or the combination of 20 mM glucose and 10 mM arginine were separated by 5-min "rest periods" during which the perfusate was returned to the baseline. Samples (2.7 ml each) were collected every minute for determination of amylin and insulin concentrations in chilled tubes containing 0.3 ml of 0.15 M NaCl, 0.05 M Na2EDTA, and 0.3 M benzamidine.
Streptozotocin treatment of rats. Male Wistar rats were given a single dose of either 30 or 65 mg/kg of streptozotocin dissolved in phosphate-buffered saline via the tail vein. Animals that received 65 mg/kg of streptozotocin were treated with insulin (2 U of isophane insulin twice daily) to prevent ketonuria and minimize hyperglycemia. Six to ten days later insulin and amylin secretion were studied by pancreatic perfusion.
Results
As shown in Fig. I A, the amylin assay could detect rat amylin over a range of 300 to 10,000 pg/ml. This assay was specific for amylin in that CGRP, a neuropeptide that is 50% identical to AMYLIN or CGRP (pg/ml) the amylin sequence, and other pancreatic hormones including insulin, somatostatin-14, and glucagon did not crossreact in the assay. Furthermore the addition of human insulin and C-peptide to the assay did not inhibit the displacement of 125I-rat amylin (data not shown). With this assay amylin was measured in the effluent of perfused pancreata of normal rats under conditions known to stimulate the secretion ofinsulin. As shown in Fig. 2 A, insulin secretion rose in typical biphasic fashion in response to glucose, arginine, and the combination of the two. The insulin response was least with glucose and most with glucose plus arginine. Baseline amylin levels in the perfusate averaged 359±88 pg/ml, slightly above the approximate limits of detection of this assay (300 pg/ml). After secretogogue challenges amylin secretion rose to easily detectable levels. During the 20-mM glucose perfusion amylin rose to a maximum level of 882±138 pg/ml and in response to 10 mM arginine peaked at 1,247±308 pg/ml. The most potent stimulus for amylin secretion was the perfusion of glucose plus arginine, when the amylin concentration rose to a peak of 2,775±385 pg/ml. As shown in Fig. 1 B, the immunoreactive amylin species in the perfusate displaced the radioactive amylin tracer from the antibody in parallel to the amylin standard curve.
To determine the effects of minimally diabetogenic and fully diabetogenic doses of the f3-cytotoxin streptozotocin on amylin secretion, rats that had received streptozotocin at either 30 or 65 mg/kg of body weight were studied using the same perfusion protocol. Rats that received the high dose of streptozotocin developed severe diabetes with hyperglycemia and ketosis (plasma glucose 450±37 mg/dl). The pancreata from these animals had a marked impairment in both insulin and amylin secretion (Fig. 2 C) . Insulin did not rise above the baseline in response to glucose. The peak of the response to arginine alone or arginine plus glucose was only 60.3±3.2 ,uU/ml and 49±6.1 uU/ml, respectively, compared with a peak of 132.3±21.8 gU/ml or 224.5±41.7 uU/ml in response to these stimuli in normal animals. However, amylin was not detected in the perfusate of any of the high-dose streptozotocin-treated animals at any time.
Rats treated with the 30-mg/kg dose of streptozotocin exhibited only minimal hyperglycemia (plasma glucose 145±20 mg/dl), no ketosis, and did not require insulin therapy. Insulin secretion did not differ dramatically from that of control rats, whereas amylin secretion was markedly reduced in response to all the stimuli (Fig. 2 B) . Glucose or arginine alone resulted in detectable amylin secretion in only one out of three rats. All rats responded to the combination ofglucose plus arginine, but the peak amylin response was much lower than in the control animals (740±104 pg/ml vs. 2,775±385 pg/ml). Table I compares the estimated secretion rates for both insulin and amylin in response to the various stimuli. In normal rats the amylin secretion rate in response to glucose or arginine was 25-28% that of insulin. When the combined regimen was used, the secretion rate of amylin increased to 37% that of insulin. However, in borderline diabetes induced by pretreatment with 30 mg/kg of streptozotocin the amylin response to glucose plus arginine perfusion fell to 7.2% of the insulin response.
Discussion
These studies show that amylin and insulin are secreted simultaneously from the ,B cell, consistent with the earlier demon- In autoimmune diabetes impairment of insulin secretion is one of the first detectable manifestations, being present before the onset of clinical symptoms (18, 19) . The reduced secretion of amylin in the streptozotocin-diabetic rats raises the possibility that impaired amylin secretion is likely to be present and may actually precede the insulin abnormality in instances of3 cell injury or depletion, such as human type 1 diabetes. The possible consequences of such amylin deficiency remain to be established.
